Citius Pharmaceuticals, Inc. (CTXR)
$0.8941
Rating:
Recommendation:
Neutral
| Symbol | CTXR |
|---|---|
| Price | $0.8941 |
| Beta | 1.648 |
| Volume Avg. | 2.08M |
| Market Cap | 130.655M |
| Shares () | - |
| 52 Week Range | 0.831-2.47 |
| 1y Target Est | - |
| DCF Unlevered | CTXR DCF -> | |
|---|---|---|
| DCF Levered | CTXR LDCF -> | |
| ROE | -5918446.34% | Strong Sell |
| ROA | -5916982.91% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 8.16% | Neutral |
| P/E | - | |
| P/B | 1.11 | Strong Buy |
Latest CTXR news
About
Download (Excel)Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.